SG Americas Securities LLC Sells 46,193 Shares of Prestige Consumer Healthcare Inc. $PBH

SG Americas Securities LLC decreased its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 69.6% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 20,132 shares of the company’s stock after selling 46,193 shares during the period. SG Americas Securities LLC’s holdings in Prestige Consumer Healthcare were worth $1,193,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PBH. Massachusetts Financial Services Co. MA increased its stake in shares of Prestige Consumer Healthcare by 10.2% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company’s stock valued at $40,147,000 after acquiring an additional 60,496 shares during the last quarter. Nordea Investment Management AB raised its position in shares of Prestige Consumer Healthcare by 547.4% in the 4th quarter. Nordea Investment Management AB now owns 615,215 shares of the company’s stock valued at $37,811,000 after acquiring an additional 520,186 shares during the period. Leeward Investments LLC MA boosted its stake in Prestige Consumer Healthcare by 23.3% during the 4th quarter. Leeward Investments LLC MA now owns 387,321 shares of the company’s stock worth $23,894,000 after acquiring an additional 73,162 shares during the last quarter. Legato Capital Management LLC boosted its stake in Prestige Consumer Healthcare by 532.4% during the 4th quarter. Legato Capital Management LLC now owns 27,774 shares of the company’s stock worth $1,713,000 after acquiring an additional 23,382 shares during the last quarter. Finally, Brandes Investment Partners LP grew its holdings in Prestige Consumer Healthcare by 93.2% during the fourth quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock valued at $37,430,000 after purchasing an additional 292,744 shares during the period. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $49.38 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.25 and a current ratio of 3.57. Prestige Consumer Healthcare Inc. has a 52 week low of $42.62 and a 52 week high of $80.69. The company’s 50 day moving average price is $49.36 and its two-hundred day moving average price is $58.27. The company has a market capitalization of $2.34 billion, a P/E ratio of 12.63, a price-to-earnings-growth ratio of 1.59 and a beta of 0.35.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The company had revenue of $281.62 million during the quarter, compared to analyst estimates of $293.64 million. During the same quarter last year, the company earned $1.32 EPS. The firm’s quarterly revenue was down 5.0% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. On average, analysts expect that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on PBH. Zacks Research downgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Finally, Canaccord Genuity Group dropped their price objective on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $70.75.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the completion of the transaction, the vice president owned 42,820 shares in the company, valued at approximately $2,354,671.80. This represents a 2.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).